Why the new Alzheimer’s disease trial results are important

An early trial from a recent study conducted by the Alzheimer’s Society offers hope for those living with the disease.

What has been discovered?

Published at the beginning of May, the trial shows that a new immunosuppressant drug called donanemab slows the progression of Alzheimer’s disease in the patient by 36 per cent, up from the previous trial at 27 per cent.

This is one of two drugs which are being tested in relation to slowing down the advancement of the disease in patients which has been successful within the last 12 months.

Prior to this, there had been no breakthrough in Alzheimer’s disease drugs for over 20 years, making it a positive outlook on the future of the disease.

Why is this important?

A breakthrough drug to help slow down the progression of Alzheimer’s disease is vitally important in helping patients have the best quality of life that they can.

The trial demonstrated that the new drug slowed down the decline of everyday activities such as driving, managing finances, and doing hobbies by 40 per cent.

This would not only allow independence for longer within the patient, but also reduce the stress on those with caring responsibilities for the patient.

What impact would this have on our care plans?

If the use of a drug such as donanemab were to come into use in the United Kingdom, it would greatly influence the care plans that we put in place for helping a client diagnosed with Alzheimer’s disease.

With Synergy Complex Care, regular evaluation is put in place to monitor the requirements of each client so that they maintain appropriate support. We prioritise working openly and honestly to both respect the client and put their needs first.

If you would like to talk to us about a care plan, please do not hesitate to contact us, and we would be more than happy to help.

Posted in General.